CEO's $498K Insider Buy After Procept's 48% Stock Slide

For investors in Procept BioRobotics (PRCT), a CEO putting nearly half a million dollars into a stock that has fallen 48% often reads as a bullish insider signal. But the August 7 Form 4 filing also shows the limits of that signal: the purchase came through The Larry Wood Trust, and aggregate insider ownership is just 0.59% of the $1.2 billion company. The question is whether this is genuine contrarian conviction or a routine estate-planning transaction.

On August 7, 2026, Procept BioRobotics Corporation (PRCT) President and CEO Larry L. Wood acquired 23,900 shares of common stock through The Larry Wood Trust at a weighted average price of $20.85 per share, a transaction valued at approximately $498,315. The purchase was disclosed in an SEC Form 4 filing and analyzed by The Motley Fool on August 18, 2026. The move came as the stock closed at $20.41 on the transaction date, leaving shares down roughly 48% on a one-year basis.

“

Wood acquired 23,900 shares of common stock through The Larry Wood Trust at a weighted average price of $20.85 per share, a transaction valued at approximately $498,315.

The transaction is notable less for its absolute size than for what it reveals about insider sentiment and ownership structure. Before the purchase, Wood already held about 314,000 shares directly; the new indirect position raises his total beneficial ownership to 338,103 shares. Yet Procept's aggregate insider ownership remains just 0.59% of the $1.2 billion company, which means this transaction, while positive, is a relatively small incremental alignment signal in the context of the broader shareholder base. The fact that the purchase was made through a trust is also relevant: trust-based acquisitions can reflect estate planning or tax considerations as much as a pure market call, and investors should avoid overinterpreting a single Form 4 as a definitive bottom signal.

For context, Procept BioRobotics develops and commercializes the AquaBeam Robotic System, a minimally invasive surgical robot used for Aquablation therapy to treat benign prostatic hyperplasia (BPH). The company generates revenue from system sales, consumable supplies, and service agreements to hospitals, urology departments, and ambulatory surgical centers. The financial snapshot is mixed: trailing twelve-month revenue reached $337.3 million, but the company still reported a net loss of $109.8 million over the same period. That combination of growing revenue and ongoing losses is common among surgical robotics and medical device companies investing heavily in commercialization, but it also explains why the stock has been vulnerable to the 48% decline.

The insider purchase mechanics carry a modest but real informational signal. Wood paid $20.85 per share, about 2.2% above the $20.41 close on August 7, indicating a willingness to buy at a slight premium rather than waiting for a lower fill. In the insider-following framework, officers typically sell for diversification or liquidity reasons, while buys are generally considered more informative because they represent a discretionary use of personal capital. However, that signal is tempered by the trust structure, the modest percentage of insider ownership, and the fact that executives can be wrong about timing, particularly in a volatile, high-multiple medical device sector.